Takeda Announces U.S. Corporate Social Responsibility (CSR) Program Aimed to Help Reduce Social Disparities

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that it is enhancing its Corporate Social Responsibility (CSR) Program in the U.S., making an initial commitment of $20 million its first year supporting organizations in the U.S. to help improve equity among underrepresented communities in the areas of health, education, the environment and access to nutrition/food. Takeda also announced its current 2021 U.S. CSR Program grant recipients, including 20 organizations who will share $16,595,000 in total grants.

"Achieving better health outcomes requires a multi-faceted approach and a more holistic view of health and well-being," said Ramona Sequeira, President, US Business Unit and Global Portfolio Commercialization, Takeda Pharmaceutical Company Limited. "Our philanthropic efforts in the U.S. focus on multiple areas including reducing social disparities, improving access to medicines and diagnosis, achieving environmental sustainability, promoting equitable educational opportunities and ensuring healthy food sources for vulnerable individuals and families. We're looking forward to growing our U.S. CSR Program over the coming years and are proud to partner with organizations located in the communities where many of our employees live and work ? including our U.S. hub in Massachusetts."

Takeda's U.S. CSR grant applications are reviewed by an internal review committee, on a rolling basis and approved through a formal governance process. Takeda partners with local and regional organizations who align with our philanthropic focus areas, share our values and our commitment to improving people's lives for the better. Takeda's 2021 U.S. CSR grantees include:

Promoting Food System Equity

Takeda is supporting the following organizations which are increasing food system equity for vulnerable families in communities around the country:

• Daily Table ? Healthy Grocer for All Program
• Food for Free ? Just Eats Program
• Greater Boston Food Bank ? Mobile Market Program
• Northern Illinois Food Bank ? Mobile Market Program
• The Food Project ? Growing Leaders, Growing Communities Program
• West End House ? Family Food Program

Promoting Greater Educational Equity

Takeda's funding of the following organizations will help advance K-8 math programs to promote greater educational equity:

• City Year ? Boston STEM Program
• Learn Fresh ? NBA Math Hoops Program
• Lesley University ? Culturally Relevant Math Expressions Program
• STEM Next ? Million Girls Moonshot Program
• Tutoring Plus ? After School Tutoring and Mentoring Program
• Young People's Project ? Math and STEM Literacy Program

Promoting Health Equity

Takeda is supporting the following organizations with programs aimed at creating social, physical and economic environments that promote health equity for all:

• Boston Healthcare for the Homeless ? Horizon Family Clinic
• Community Servings ? Food is Medicine Program
• Inner City Weightlifting ? Grow and Strengthen Core Program
• Health Leads ? Catalyzing Hyper-Local Health Systems Transformation Program
• Urban Edge ? Strong Start Roxbury Program

Supporting Healthier Environments

The following organizations are receiving funding for climate resiliency initiatives building toward a healthier environment:

• American Red Cross ? Annual Disaster Giving Fund Program
• CitySprouts ? Young Leaders Program
• Mystic River Watershed Association ? Wicked Hot Mystic Program

Learn more about Takeda's U.S. Corporate Social Responsibility Program and our philanthropic strategy here. For more details about Takeda's Global CSR Program, you can find them here.

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com.